Index Note: Page numbers of article titles are in boldface type. A Ablative therapies, transurethral needle ablation, Adverse events, sexual side effects of BPH Aging, and incidence of BPH associated with LUTS, 293 and prevalence of BPH associated with LUTS, 291 Alpha-blockers, for treatment of BPH, 311 323, 352, 394 395, 398 versus 5-alpha reductase inhibitors for LUTS and, 317 319 in combination with 5-alpha-reductase inhibitors, 328 332 development of selective, 312 315 efficacy of different class formulations, 352 sexual side effects of, 394 395, 398 in combinations with 5-alpha-reductase inhibitors, 398 comparisons of, 395 nonselective, 394 selective, 394 395 Alpha-reductase inhibitors, 5-, for treatment of LUTS and BPH, 325 336, 352 353, 396 398 versus alpha-blockers for LUTS/BPH, 317 319 with alpha-blockers, 328 332 with phosphodiesterase type 5 inhibitors, 332 effects on PSA and prostate cancer risk, 328 efficacy of different class formulations, 352 353 dutasteride, 326 327 finasteride, 325 326 sexual side effects of, 396 398 in combination with alpha blockers, 398 physiologic basis to sexual dysfunction, 396 study-specific outcomes, 396 398 American Urological Association, guidelines for diagnostic work-up of LUTS, 305, 306 307 Urol Clin N Am 43 (2016) 413 417 http://dx.doi.org/10.1016/s0094-0143(16)30045-3 0094-0143/16/$ see front matter Anatomy, of human and rodent prostate, 281 283 Androgens, interaction with BPH, 407 410 Animal models, in study of BPH, 284 285 Anticholinergics, efficacy of different class formulations, 353 sexual side effects of BPH treatment with, 398 Antimuscarinics, for treatment of LUTS, 337 349 clinical efficacy, 338 340 clinical safety, 340 341 mechanisms of action, 338 B Benign prostatic hyperplasia (BPH), 5-alpha-reductase inhibitors, 325 336 with alpha-blockers, 328 332 with phosphodiesterase type 5 inhibitors, 332 effects on PSA and prostate cancer risk, 328 dutasteride, 326 327 finasteride, 325 326 alpha-blockers for treatment of, 311 323 versus 5-alpha reductase for LUTS and, 317 319 development of, 312 315 associated with LUTS, epidemiology of, 289 297 efficacy of different class formulations in medical management of, 351 356 phosphodiesterase type 5 inhibitors, 353 354 urologic.theclinics.com
414 Index Benign (continued) treatment resistance and complications, 354 prostate anatomy, embryology and etiology of, 279 288 anatomy of human and rodent prostate, 281 283 animal models in study of, 284 285 etiology, 283 284 human and rodent prostate embryology, 280 281 prostatic urethral lift for LUTS secondary to, sexual side effects of treatments, 393 404 medications, 394 398 surgical treatments, 398 401 testosterone and the prostate, 405 412 androgens and interaction with BPH, 406 410 Benign prostatic obstruction, choosing treatment for, 377 384 Beta-3 agonists, for treatment of LUTS, 337 349, 353 clinical efficacy, 341 clinical safety, 341 342 efficacy of different class formulations, 353 mechanism of action, 341 Bladder outlet obstruction, alpha-blockers for treatment of LUTS in BPH, 311 323 C Canadian Urological Association, guidelines for diagnostic work-up of LUTS, 306 307 Creatinine, serum, in diagnostic work-up of LUTS, 301 D Dutasteride, 326 327 E Ejaculatory dysfunction, sexual side effects of BPH Embryology, of human and rodent prostate, 280 281 Endoscopy, in diagnostic work-up of LUTS, 305 306 Epidemiology, of BPH associated with LUTS, 289 297 Erectile dysfunction, sexual side effects of BPH Ethnicity, and incidence of BPH associated with LUTS, 293 and prevalence of BPH associated with LUTS, 292 European Association of Urology, guidelines for diagnostic work-up of LUTS, 306 307 F Finasteride, 325 326 Frequency-volume charts, in work-up of LUTS, 300 G Greenlight photovaporization, of the prostate, Guidelines, for diagnostic work-up of LUTS, 305, 306 307 American Urologic Association, 305, 306 307 Canadian Urological Association, 307 European Association of Urology, 306 H History, patient, in diagnostic work-up of LUTS, 299 300 additional history, 300 frequency-volume charts, 300 symptom score, 299 300 Holmium laser enucleation, of prostate, 380 381, 400 complications, 380 functional results, 380
Index 415 indications, 380 learning curve, 380 381 Hypogonadism, natural history of testosterone and, I Imaging, in diagnostic work-up of LUTS, 300 306 Incidence, of BPH associated with LUTS, 291 293 by age and severity, 293 overall, 292 293 by race and ethnicity, 293 International Prostate Symptom Score (IPSS), 299 300 L Laser enucleation, holmium, of prostate, 380 381, 400 complications, 380 functional results, 380 indications, 380 learning curve, 380 381 Lower urinary tract symptoms (LUTS), antimuscarinics for, 337 349 beta-3 agonists for, 337 349 diagnostic work-up of, 299 309 guideline overview, 306 307 imaging and additional testing, 300 306 additional imaging, 306 endoscopy, 305 306 peak urine flow rate, 302 303 postvoid residual urine volume, 302 pressure-flow studies, 303 304 prostate ultrasonography, 304 305 prostate-specific antigen, 301 302 serum creatinine, 301 urine studies, 300 301 patient history, 299 300 additional history, 300 frequency-volume charts, 300 symptom score, 299 300 physical examination, 300 efficacy of different class formulations in medical management of, 351 356 phosphodiesterase type 5 inhibitors, 353 354 treatment resistance and complications, 354 epidemiology of BPH associated with, 289 297 phosphodiesterase inhibitors for, 337 349 prostatic urethral lift for LUTS secondary to BPH, testosterone and the prostate, 405 412 LUTS. See Lower urinary tract symptoms. M Medical management, of LUTS and BPH, 5-alpha-reductase inhibitors, 325 336 effects on PSA and prostate cancer risk, 328 alpha-blockers for treatment of, 311 323 versus 5-alpha reductase for LUTS and, 317 319 development of, 312 315 efficacy of different class formulations, 351 356 phosphodiesterase type 5 inhibitors, 353 354 treatment resistance and complications, 354 sexual side effects of, 394 398 Microwave therapy, transurethral, for BPH, sexual side effects of, 400 Minimally invasive therapy, prostatic urethral lift,
416 Index N Needle ablation, transurethral, for BPH, sexual side effects of, 400 O Obstruction, benign prostatic, choosing treatment for, 377 384 bladder outlet, alpha-blockers for treatment of, 311 323 Overactive bladder, antimuscarinics for, 338 341 beta-3 agonists for, 341 342 phosphodiesterase inhibitors for, 342 345 P Peak urine flow rate, in diagnostic work-up of LUTS, 302 303 Phosphodiesterase type 5 inhibitors, in combination with 5-alpha-reductase inhibitors, 332 efficacy of different class formulations, 353 354 sexual side effects of, 398 for treatment of LUTS, 337 349, 398 clinical efficacy, 343 clinical safety, 343 345 mechanism of action, 342 343 Photoselective vaporization, of prostate, sexual side effects of, Photovaporization, greenlight, of the prostate, Physical examination, in diagnostic work-up of LUTS, 300 Postvoid residual urine volume, in diagnostic work-up of LUTS, 302 Pressure-flow studies, in diagnostic work-up of LUTS, 303 304 Prevalence, of BPH associated with LUTS, 291 293 by disease severity, 291 292 overall and by age, 291 by race and ethnicity, 292 Proscar. See Finasteride. Prostate, anatomy of, 281 283 benign prostatic hyperplasia, etiology of, 283 284 embryology and postnatal development of, 280 281 testosterone and, 405 412 ultrasonography of, in diagnostic work-up of LUTS, 304 305 Prostate cancer, effects of 5-alpha-reductase inhibitors on risk of, 328 Prostate-specific antigen (PSA), effects of 5-alpha-reductase inhibitors on, 328 Prostatectomy, open simple, sexual side effects of, 400 robotic-assisted simple, complications, 389 cost comparison, 389 duration of catheterization, 389 functional, 389 hospital duration of stay, 389 operative blood loss and transfusion, 389 operative time, 387 388 advancement of bladder neck mucosa, 387 bladder closure, 387 development of lateral and anterior plane, 387 development of posterior plane, 386 387 patient setup, 386 postoperative care, 387 preoperative evaluation and preparation, 386 prostate exposure, 386 transection of urethra and removal of adenoma, 387 Prostatic hyperplasia, benign. See Benign prostatic hyperplasia (BPH). Prostatic obstruction, benign. See Benign prostatic obstruction (BPO). Prostatic urethral lift, for LUTS secondary to BPH,, 400 durability, 377 effectiveness, 363 365 safety, 365 366 sexual function preservation, 366 367 immediate postoperative care, 361 362 preoperative planning, 358 359 preparation and patient positioning, 359 procedure, 360 361 surgical approach, 359 360 R Race, and incidence of BPH associated with LUTS, 293 and prevalence of BPH associated with LUTS, 292 Rats, anatomy of prostate in, 281 283 in animal models for study of BPH, 284 285
Index 417 embryology of prostate in, 280 281 Risk factors, for BPH associated with LUTS, 290 291 Robotic-assisted simple prostatectomy, complications, 389 cost comparison, 389 duration of catheterization, 389 functional, 389 hospital duration of stay, 389 operative blood loss and transfusion, 389 operative time, 387 388 advancement of bladder neck mucosa, 387 bladder closure, 387 development of lateral and anterior plane, 387 development of posterior plane, 386 387 patient setup, 386 postoperative care, 387 preoperative evaluation and preparation, 386 prostate exposure, 386 transection of urethra and removal of adenoma, 387 S Serum creatinine, in diagnostic work-up of LUTS, 301 Sexual function, preservation of, with prostatic urethral lift, 366 367 Sexual side effects, of BPH medications, 394 398 surgical treatments, 398 401 Silodosin, for LUTS in BPH, 316 317 Simple prostatectomy. See Prostatectomy. Storage lower urinary tract symptoms, antimuscarinics for, 338 341 beta-3 agonists for, 341 342 phosphodiesterase inhibitors for, 342 345 Surgical management, of benign prostatic obstruction, 377 384 of LUTS and BPH, prostatic urethral lift, T sexual side effects, 398 401 Testosterone, and the prostate, 405 412 Transurethral microwave therapy, for BPH, sexual side effects of, 400 Transurethral needle ablation, for BPH, sexual side effects of, 400 Transurethral resection of prostate (TURP), bipolar, for BPO, 379 complications, 379 functional results, 379 indications, 379 learning curve, 379 for BPH, sexual side effects of, 399 400 bipolar versus monopolar, 399 400 ejaculatory dysfunction, 399 erectile dysfunction, 399 monopolar, for BPO, 378 379 complications, 378 379 functional results, 378 indications, 378 learning curve, 379 U Ultrasonography, of prostate, in diagnostic work-up of LUTS, 304 305 Urinary retention, acute, alpha-blockers for treatment of, 317 Urine studies, in diagnostic work-up of LUTS, 300 301 V Vaporization, photoselective, of prostate, sexual side effects of, Voiding diaries, in work-up of LUTS, 300